Hehehe! Here’s the rest!
$BioLine Rx (BLRX.US)$ BioLineRx And Ayrmid Entered Into A License Agreement For Motixafortide (Commercially Sold In The US As Aphexda), BioLineRx Will Receive A $10M Upfront Payment And Is Also Eligible To Receive Up To An Additional $87M Of Potential Commercial Milestones, Plus Royalties Between 18%-23% On Net Sales Of Aphexda
Aphexda is Biolinerx's FDA-Approved Stem Cell Mobilization Agent Indicated In Combination With Filgrastim For Collection And Subsequent Autologous Transplantation In Patients With Multiple Myeloma.BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23%.BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC.BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company's pipeline and expansion.Transactions enable significant reduction in BioLineRx's operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases –
Aphexda is Biolinerx's FDA-Approved Stem Cell Mobilization Agent Indicated In Combination With Filgrastim For Collection And Subsequent Autologous Transplantation In Patients With Multiple Myeloma.BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23%.BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC.BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company's pipeline and expansion.Transactions enable significant reduction in BioLineRx's operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases –
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
